Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2004

View Archived Issues

New formulations comprising epinastine

Antibacterial ketolides claimed by Taisho

New compounds for neurological disorders described in a patent

Ono claims elastase inhibitors for COPD, pulmonary emphysema, rheumatoid arthritis, etc.

Researchers at Aponetics describe apoptosis-inducing agents

New HDAC inhibitors described by Roche

New antioxidants in early development at Japan Science and Technology

Camptothecin combinations for the treatment of tumors

MT-201 cleared to enter phase II U.S. trial in metastatic breast cancer

BioMarin and Suntory form strategic partnership for Phenoptin

Enrollment completed in phase II lipodystrophy study of EG-005

Pipeline progression at Antisoma

Gedeon Richter and Forest collaborate on atypical antipsychotic RGH-188

deCODE genetics and Roche establish PDE4 inhibitor collaboration

Confirmatory phase III study for Frova opens enrollment

SRP-299 discontinued for moderate to severe pediatric atopic dermatitis

Sirna-027 enters phase I study for wet AMD

Positive preliminary results from phase I/II study of PA-457

Specific Akt inhibitor shows antiproliferative and antiapoptotic effects

Novel orally available PDGFR inhibitors from Millennium

VEGFR vaccine blocks initiation and progression of atherosclerosis

Cytochroma cleared to begin Canadian phase Ia study of CTA-018 for psoriasis

Pivotal generalized anxiety disorder study under way for ocinaplon

Phase II NSCLC trial of KOS-862 discontinued

Tysabri approved for multiple sclerosis

Intravenous use of Remodulin approved for pulmonary arterial hypertension

Nicaraven cardioprotective in sepsis model

Update on the effects and safety of veglin in refractory cancer

Statins may decrease mortality in pneumonia patients

ChimeriVax-JE reported safe and immunogenic in healthy volunteers

Antitumor efficacy and safety of a panitumumab-based regimen in colorectal cancer

Isatoribine reduces HCV viral load in patients with chronic hepatitis C

Therapeutic benefits of the Enteryx(R) procedure in GERD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...